Immune response to Clostridium difficile infection

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 11, 1996, Pages 1048-1053

  Kelly, Ciarán P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibiotic associated diarrhoea; Antibody; Clostridium difficile; Enterotoxin; Immune response; Immunization; Infectious diarrhoea; Intestinal inflammation; Mucosal immunity; Toxin; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL ANTIGEN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; BACTERIAL IMMUNITY; BACTERIAL INFECTION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; DIARRHEA; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INTESTINE INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW;

EID: 0029842638     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199611000-00004     Document Type: Review

References (68)

1. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficile colitis. N Engl J Med 1994, 330:257-262.
2. Borriello SP: The influence of the normal flora on Clostridium difficile colonisation of the gut. Ann Med 1990, 162:678-684.
3. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, et al.: Diminished Clostridium difficile toxin A sensitivity in newborn rabbits is associated with decreased toxin A receptor. J Clin Invest 1992, 90:822-829.
4. Dove CH, Wang SZ, Proce SB, Phelps CJ, Lyerly DM, Wilkins • TD, et al.: Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 1990, 58:480-488. The cloning and sequencing of the toxin A molecule as described in this study is a major step toward defining the active regions of this large molecule. Ultimately this may lead to the development of vaccines targeted toward the key epitopes which mediate toxin effects.
5. von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, • Schulze J, Sauerborn M: Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B. Med Microbiol Immunol 1990, 179:271-279. The Cloning and sequencing of toxin B is a major step toward defining the active regions of the toxin molecule. Ultimately this may facilitate targeted vaccine development (see reference 4).
6. Lyerley DM., Lockwood DE, Richardson SH, Wilkins TD: Biological activities of toxins A and B of Clostridium difficile. Infect Immun 1982, 35:1147-1150.
7. Triadafilopoulos G, Pothoulakis C, O'Brien M, LaMont JT: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987, 93:273-279.
8. Pothoulakis C, Barone LM, Ely R, Faris B, Clark ME, Franzblau C, et al.: Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem 1986, 261:1 316-1 321.
9. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacheri J, •• Bishof G, et al.: Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995, 95:2004-2011. Toxin B has little enterotoxic effect in animals. However, this study indicates that toxin B may be even more damaging than toxin A when applied to the human colon. This has important implications for human vaccine development and for other novel treatments, such as passive immunotherapy, aimed at binding to and neutralizing C. difficile toxins.
10. Arnon SS, Mills DC, Day PA, Hendrickson RV, Sullivan NM, Wilkins TD: Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis. J Pediatr 1984, 101:34-40.
11. Lylerly DM, Krivan HC, Wilkins TD: Clostridium difficile: Its disease and toxins. Clin Microbiol Rev 1988, 1:1-18.
12. Lyerly DM, Phelps CJ, Toth J, Wilkins TD: Characterization of •• toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 1986, 54:70-76. A monoclonal antibody to toxin A neutralizes its enterotoxic effects without inhibiting cytotoxicity indicating that these two effects are mediated by different portions of the toxin A molecule (see also references 17 and 33).
13. Martinez RD, Wilkins TD: Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of Clostridium difficile J Med Microbiol 1992, 36:30-36.
14. Baldacini O, Girardot R, Green GA, Rihn B, Monteil H: Comparative study of immunological properties and cytotoxic effects of Clostridium difficile toxin B and Clostridium sordellii toxin L. Toxicon 1992, 30:129-140.
15. Krivan HC, Clark GF, Smith DF, Wilkins TD: Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence 1-3Galβ1-4GlcNAc. Infect Immun 1986, 53:573-581.
16. Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JR, Theoharides TC, et al.: Characterization of rabbit ileal receptors for Clostridium difficile toxin A: Evidence for a receptor-coupled G protein. J Clin Invest 1991, 88:119-125.
17. Frey SM, Wilkins TD: Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun 1992, 60:2488-2492.
18. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories •• K: Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995, 375: 500-503. This study identifies the intracellular enzymatic action of toxin B. Toxin B catalyses the glucosylation of the amino acid threonine at position 37 of the small GTP-binding protein RhoA. This modification of RhoA results in the disaggregation of actin filaments and leads to cell rounding.
19. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Aktories K: • The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 1995, 270:13932-13936. This study identifies the intracellular enzymatic action of toxin A which is identical to that described for toxin B (see reference 18). Toxin A catalyses the glucosylation of certain Rho proteins (RhoA, Rac1 and Cdc42Hs). Toxin A, like toxin A, uses UDP-glucose as its substrate and glucosylates a threonine residue in position 37 of the RhoA molecule.
20. Miller PD, Pothoulakis C, Baeker TR, LaMont JT, Rothstein TI: Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin a and calcium ionophore. Cell Immunol 1990, 126:155-163.
21. Flegel WA, Muller F, Daubener W, Fisher H-G, Hadding U, Northoff H: Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun 1991, 59:3659-3666.
22. Linevsky JK, Keates S, Pothoulakis C, LaMont JT, Kelly CP: IL-8 release and neutrophil activation by Clostridium difficile toxinexposed monocytes. Gastroenterology 1995, 108:A863.
23. Pothoulakis C, Karmeli F, Kelly CP, Eliakim R, Joshi MA, O'Keane CJ, et al.: Ketolifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology 1993, 105:701-707.
24. Kurose I, Pothoulakis C, LaMont JT, Anderson DC, Paulson JC, Miyasaka M, et al.: Clostridium difficile toxin A-induced microvascular dysfunction: role of histamine. J Clin Invest 1994, 94:1919-1926.
25. Castagliuolo I, LaMont JT, Letourneau R, Kelly C, O'Keane JC, Jaffer A, et al.: Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1994, 107:657-665.
26. Pothoulakis C, Sullivan R, Melnick DA, Triadafilopoulos G, Gadenne A-S, Meshulam T, et al.: Clostridium difficile toxin A stimulates calcium release and chemotactic response in human granulocytes. J Clin Invest 1988, 81:1741-1745.
27. Kelly CP, Becker S, Linevsky JT, Joshi MA, O'Keane JC, Dickey BF, et al.: Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 1994, 93:1257-1265.
28. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider RM, et. al.: CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 1994, 91:947-951.
29. Allo M, Silvia J, Fekety R, Rifkin GD, Waskin H: Prevention of • clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology 1979, 76:351-355. An early demonstration of passive immunization against C. difficile colitis in animals using cross-reactive C. sordellii antitoxin.
30. Libby JM, Jortner BS, Wilkins TD: Effects of the two toxins of • Clostridium difficile in antibiotic associated cecitis in hamsters. Infect Immun 1982, 36:822-829. This study demonstrated that active immunization against C. difficile toxins A and B protects against C. difficile colitis in animals.
31. Fernie DS, Thomson RO, Batty I, Walker PD: Active and passive immunization against antibiotic associated caecitis in hamsters. Develop Biol Standerd 1983, 53:325-332.
32. Kim PH, Iaconis JP, Rolfe RD: Immunization of adult hamsters • against Clostridium difficile associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987, 55:2984-2992. Immunization of hamsters with toxoid A alone was protective in this study whereas toxoid B immunization was not. This agrees with the observation that, in animal models, toxin A rather than toxin B is the prime enterotoxin. Oral passive immunization via breast milk was also demonstrated. Immunized female hamsters secreted antitoxin in their milk which prevented C. difficile colitis in suckling infant hamsters.
33. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R: •• Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991, 59: 1192-1195. Mice can be passively immunized using a monoclonal antibody directed against the repeating unit of toxin A demonstrating the importance of this receptor-binding site in mediating toxin A-induced enterotoxicity.
34. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder •• RW, et al.: Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1982, 148:93-100. Approximately two thirds of the adult population have serum IgG antibodies to toxins A and B. Increased serum anti-C. difficile antibody levels are evident in some patients following an episode of C. difficile diarrhoea.
35. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, •• Flores A: Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991, 118:633-637. Childre'n with relapsing C. difficile diarrhoea were found to have low serum IgG antibody levels against toxin A. Treatment with pooled human gamma globulin administered intravenously resulted in a marked rise in serum IgG antitoxin A levels and was associated with clinical improvement.
36. Kelly CP, Pothoulakis C, Orellana J, LaMont JT: Human colonic • aspirates containing IgA antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992, 102:35-40. Colonic aspirates from healthy individuals frequently contained secretory IgA antibody to toxin A. The binding of toxin A to its intestinal receptor was inhibited by aspirates with high antitoxin A levels. This is the presumed mechanism whereby intestinal secretory antibody may protect against C. difficile toxin-induced colitis.
37. Nakamura S, Mikawa M, Nakashio S, Takabatake M, Okado I, • Yamakawa K, et al.: Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981, 25:345-351. The sera of young adults who carried C. difficile frequently had toxin neutralizing activity whereas the sera of elderly carriers did not. A failing humoral immune response may contribute to the high rate of symptomatic C. difficile infection in the elderly and the infirm.
38. Wada N, Nishida N, Iwaki S, Ohi H, Miyawaki T, Taniguchi N, • et al.: Neutralizing activity against Clostridium difficile toxin in the supernatants of cultured colostral cells. Infect Immun 1980, 29:545-550. The supernatants of cultured human colostral cells from some individuals neutralize the cytotoxic effects of toxins A and B. This presumably reflects a secretory antibody response to C. difficile toxins.
39. Kim K, Pickering LK, DuPont HL, Sullivan N, Wilkins T: In vitro • and in vivo neutralizing activity of human colostrum against purified toxins A and B of Clostridium difficile. J Infect Dis 1984, 150:57-62. Like the previous study this report indicates a secretory antibody response to C. difficile toxins in human colostrum.
40. Thompson CM, Gilligan PH, Fisher MC, Long SS: Clostridium difficile cytotoxin in a pediatric population. Am J Dis Child 1983, 137:271-274.
41. Tullus K, Aronsson B, Marcus S, Mollby R: Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 1989, 8:390-393.
42. Cooperstock MS, Steffen E, Yolken R, Onderdonk A: Clostridium difficile in normal infants and sudden infant death syndrome: an association with infant formula feeding. Pediatrics 1982, 70:91-95.
43. Cooperstock M, Riegle L, Woodruff CW, Onderdonk A: Influence of age, sex, and diet on asymptomatic colonization of infants with Clostridium difficile. J Clin Microbiol 1983, 17:830-833.
44. Larson HE, Barclay FE, Honour P, Hill ID: Epidemiology of Clostridium difficile in infants. J Infect Dis 1982, 146:727-733.
45. Aronsson B, Granstrom M, Mollby R, Nord CE: Enzyme-linked •• immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea. J Immunol Methods 1983, 60:341-350. Increased serum anti-C. difficile antibody levels and toxin B neutralizing activity were evident in some patients with C. difficile colitis. Lack of an antibody response seemed to correlate with more severe colitis.
46. Aronsson B, Granstrom M, Mollby R, Nord CE: Serum antibody •• response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985, 13:97-101. Higher levels of serum IgG antibody against C. difficile toxins (particularly toxin B) were found in patients with mild, self-limiting C. difficile diarrhoea as compared with those with more severe diarrhoea. Patients with relapsing diarrhoea had the lowest antitoxin levels. The appearance of neutralizing serum antibodies frequently correlated with clinical recovery from diarrhoea.
47. Johnson S, Gerding DN, Janoff EN: Systemic and mucosal anti• body responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992, 166:1287-1294. Most patients with C. difficile diarrhoea demonstrated systemic and mucosal antibodies to toxin A. In contrast to other reports this study found no correlation between serum or intestinal antibody responses and disease course.
48. Fairweather SD, George RH, Keighley MRB, Youngs D, Burdon DW: Arthritis in pseudomembranous colitis associated with an antibody to Clostridium difficile toxin. J R Soc Med 1980, 73:524-525.
49. Lishman AH, Al-Jumaili IJ, Record CO: Antitoxin production in antibiotic-associated colitis? J Clin Pathol 1981, 34:414-415. An early report of toxin neutralizing activity in the serum of a patient with C. difficile diarrhoea.
50. Warny M, Vaerman J-P, Avesani V, Delmee M: Human antibody •• response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994, 62:384-389. Both serum IgG and faecal IgA antitoxin A antibody levels were lower in patients with prolonged, relapsing C. difficile diarrhoea than in patients with diarrhoea of short duration.
51. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RYY: •• Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993, 16:S239-5244. Asymptomatic carriers of C. difficile had high levels of serum IgA and IgM antibodies against C. difficile somatic cell antigens (rather than toxins). Patients with C. difficile diarrhoea had lower antibody levels.
52. Aronsson B, Granstrom M: Immunological response to Clostridium difficile infection. In Clostridium difficile: its Role in Intestinal Disease. Academic Press; 1988:99-112.
53. Kelly CP, LaMont JT: Treatment of Clostridium difficile diarrhoea and colitis. In Gastrointestinal Pharmacotherapy. Edited by Wolfe MM. Philadelphia: WB Saunders; 1993:199-212.
54. Salcedo I, Keates S, Pothoulakis C, Castagliuolo I, LaMont JT, Kelly CP: Intravenous gammaglobulin, a novel treatment for severe unresponsive Clostridium difficile colitis. Gastroenterology 1996, 110:A1007.
55. Tjellström B, Stenhammar L, Eriksson S, Magnusson K-E: Oral immunoglobulin A supplementation in treatment of Clostridium difficile enteritis. Lancet 1993, 341:702.
56. Tacket CO, Binion SB, Bostwick E, Losonsky GL, Roy MJ, Edelman R: Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992, 47:276-283.
57. Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, et al: Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 1988, 318: 1240-1243.
58. Davidson GP, Whyte PBD, Daniels E, Franklin K, Nunan H, McCloud PI, et al.: Passive immunization of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989, ii:709-712.
59. Nord J, Ma P, DiJohn D, Tzipori S, Tacket CO: Treatment of cryptosporidial diarrhoea in AIDS patients with bovine hyperimmune colostrum. AIDS 1990, 4:581-584.
60. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD: Passive immu• nization of hamsters against disease caused by Clostridium difficile by use of a bovine immunoglobulin G concentrate. Infect Immun 1991, 59:2215-2218. An anti-Clostridium difficile bovine immunoglobulin concentrate was produced from the colostrum of immunized cows. This agent neutralized the cytotoxicity of C. difficile culture filtrate and, when administered intragastrically, protected hamsters against C. difficile diarrhoea and death.
61. Kelly CP, Vavva F, Castagliuolo I, Bostwick E, Keates S, LaMont JT, et al.: Anti-Clostridium difficile bovine immunoglobulin concentrate blocks cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996, 40:373-379.
62. Chetham ST, Keates S, Pothoulakis C, Castagliuolo I, Bostwick EF, LaMont JT, et al.: C. difficile toxin neutralizing activity in human feces after oral anti-C. difficile bovine immunoglobulin concentrate. Gastroenterology 1996, 110:A882.
63. McFarland LV, Mulligan ME, Kwok RYY, et al.: Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320:204-210.
64. Bender BS, Bennett R, Laughton BE, et al.: Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986, ii:11-13.
65. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, et al.: Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 1992, 117:297-302.
66. Clemens JD, Sack DA, Harris JR, et al.: Field trials of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
67. Kamiya S, Yamakawa K, Meng XQ, Ogura H, Nakamura S: Production of monoclonal antibody to Clostridium difficile toxin A which neutralises enterotoxicity but not haemagglutination activity. FEMS Microbiol Lett 1991, 65:311-315.
68. Torres JF, Lyerly DM, Hill JE, Monath TP: Evaluation of formalin-• inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995, 63:4619-4627. In hamsters a combination of parenteral and mucosal (intranasal) immunization provided the best protection against C. difficile disease. The inclusion of a mucosal route of immunization may generate a substantial secretory antibody response and thereby result in more effective intestinal immunity.